Clinical Trials
2 trialsNCT03785249 2025-09-30
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Mirati Therapeutics Inc.
Phase 1/2 Active not recruiting
NCT02501096 2023-07-20
A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors
Eisai Inc.
Phase 1/2 Completed